
Autolus Therapeutics plc
100
Recent developments include strong commercial momentum for AUCATZYL with significant revenue growth, ongoing clinical trial progress in pediatric oncology and autoimmune indications, regulatory designations, and strategic financing arrangements.
- Autolus reported net product revenue of $41.2 million for Q3 2026, up from $21.1 million in the prior year period, driven by increased demand and UK market launch [N1].
- The Phase 2 portion of the CATULUS trial for obe-cel in pediatric r/r B-ALL is progressing with data anticipated by end of 2027 [N2].
- Updated data from the Phase 1 CARLYSLE trial in severe refractory systemic lupus erythematosus will be presented at the American College of Rheumatology Annual Meeting in November 2026 [N1].
- The pivotal Phase 2 LUMINA study for obe-cel in refractory lupus nephritis is enrolling across five countries with data expected in 2028 [N3].
- The FDA granted RMAT designation to obe-cel for treatment of SLE and lupus nephritis on September 9, 2026 [N3].
- A Phase 1 dose escalation trial of obe-cel in progressive multiple sclerosis is ongoing, with initial data presentations planned for October 2027 [N1].
- The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing with initial data expected at the ASH meeting in December 2026 [N1].
- Autolus entered a senior secured notes facility with Perceptive in July 2026, issuing $75 million initially with additional borrowing capacity and potential tranches tied to revenue milestones [N1].
Autolus Therapeutics plc develops and commercializes programmed T cell therapies using proprietary modular engineering technologies. Its lead product, AUCATZYL (obe-cel), is a CD19-targeting CAR T cell therapy approved for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). The company manufactures AUCATZYL at its UK facility and distributes it in the US and UK markets. Autolus is expanding obe-cel's indications to pediatric oncology and autoimmune diseases such as lupus and multiple sclerosis through ongoing clinical trials. The company employs advanced targeting and safety control technologies to enhance efficacy and manage toxicity. Autolus reported increasing product revenues driven by commercial expansion and maintains a strong liquidity position supported by a senior secured notes facility.
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company specializing in next-generation T cell therapies for cancer and autoimmune diseases. Its lead product, AUCATZYL (obe-cel), is FDA-approved for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia and commercially launched in the US and UK. The company is advancing obe-cel in pediatric oncology and autoimmune indications, including lupus and multiple sclerosis, with ongoing clinical trials and regulatory designations such as RMAT. Financially, Autolus reported $41.2 million in Q3 2026 product revenue and a net loss of $55.1 million for the quarter, with a strong liquidity position of $245.4 million cash and a current ratio of 3.72 as of September 30, 2026. The company has secured a senior secured notes facility to support operations. Risks include compliance with financial covenants and uncertainties inherent in clinical development and commercialization. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Autolus's lead product AUCATZYL has secured regulatory approvals and commercial launches in the US and UK, with growing revenues indicating market acceptance. The company’s modular T cell programming platform supports pipeline expansion into pediatric oncology and autoimmune diseases, with ongoing clinical trials and RMAT designations potentially facilitating regulatory pathways. Advanced targeting and safety technologies may improve therapeutic profiles and broaden applicability. Strategic financing arrangements provide capital to support development and commercialization activities.
Autolus faces risks from clinical development uncertainties, including the timing and outcomes of ongoing trials in pediatric oncology, lupus, and multiple sclerosis. Commercial launch in the EU is on hold, limiting geographic revenue expansion. The company has incurred significant net losses and accumulated deficits, with reliance on external financing subject to covenant compliance. Manufacturing complexities and potential toxicities inherent in CAR T therapies pose operational challenges. Regulatory and reimbursement environments may impact market access and pricing.
Autolus's competitive advantage lies in its proprietary modular T cell programming technologies that enable precise targeting, pharmacological control, and enhanced activity of T cell therapies. Its fast off-rate CAR design aims to reduce toxicity and improve T cell persistence. The company’s integrated manufacturing facility supports commercial supply, and regulatory approvals in multiple regions establish market access. Its pipeline diversification into oncology and autoimmune indications, combined with advanced safety switches and tumor microenvironment shielding, positions it to address limitations of existing therapies and potentially offer differentiated treatment options.
• Financial Covenant Compliance: Autolus's obligations under its senior secured notes facility are secured by substantially all assets and subject to financial covenants. Failure to comply could lead to acceleration of debt and enforcement actions, materially affecting liquidity and operations.
• Clinical Development Uncertainty: The success of ongoing clinical trials in pediatric oncology, lupus nephritis, and multiple sclerosis is uncertain. Delays or unfavorable results could impact product development and commercialization plans.
• Regulatory and Market Access Risks: Commercial launch in the EU is currently on hold, and reimbursement decisions in various markets may affect sales potential. Transition to U.S. domestic issuer status will increase compliance costs.
• Manufacturing and Safety Challenges: Manufacturing CAR T therapies is complex and costly. Potential toxicities such as cytokine release syndrome and neurologic events require management through safety switches, impacting clinical and commercial operations.
Business trends: Expansion of AUCATZYL commercial sales in US and UK, clinical development progress in pediatric oncology and autoimmune indications, and regulatory designations enhancing development pathways.
Execution milestones: Completion of Phase 2 pediatric r/r B-ALL trial enrollment, presentation of lupus and MS clinical data, and advancement of manufacturing and commercialization capabilities.
Key risks: Clinical trial uncertainties, financial covenant compliance under secured notes, regulatory and reimbursement challenges, and manufacturing complexities inherent to CAR T therapies.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation T cell therapies for cancer and autoimmune diseases.
- The company uses proprietary modular T cell programming technologies to engineer targeted and controlled T cell therapies designed to recognize and eliminate target cells.
- Autolus's commercial product AUCATZYL (obecabtagene autoleucel, also known as obe-cel) is approved by the FDA for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) and launched in the US in January 2025.
- AUCATZYL received conditional marketing authorization in the UK in April 2025 and was launched there in January 2026, available through the NHS.
- The European Commission granted marketing authorization for AUCATZYL in July 2025 for adult patients with r/r B-ALL, but commercial launch in the EU is currently on hold with no EU sales anticipated in 2026.
- AUCATZYL is a CD19-targeting CAR T cell therapy designed with a fast target binding off-rate to minimize excessive T cell activation.
- The company manufactures AUCATZYL at its dedicated commercial manufacturing site, the Nucleus, in Stevenage, UK, with Cardinal Health 105, LLC as the US commercial distribution partner.
- Autolus is advancing obe-cel in additional oncology indications including pediatric B-ALL and B-NHL, with Phase 1b/2 CATULUS trial ongoing and Phase 2 cohort enrollment expected to complete in the first half of 2027.
- Obe-cel is also being developed for autoimmune diseases, including severe refractory systemic lupus erythematosus (SLE) and lupus nephritis (LN), with ongoing Phase 1 CARLYSLE and Phase 2 LUMINA trials.
- The FDA granted regenerative medicine advanced therapy (RMAT) designation to obe-cel for treatment of pediatric r/r B-ALL and for SLE and LN indications.
- Autolus has initiated a Phase 1 dose escalation trial of obe-cel in progressive multiple sclerosis (MS), with initial data presentations planned for late 2027.
- The company’s pipeline includes four programs targeting eight hematological and solid tumor indications and two autoimmune indications, built on modular innovation with protein-based cell programming.
- Autolus employs advanced targeting technologies including fast off-rate CARs, dual-targeting CARs, pharmacological control safety switches (RQR8, RapaCasp9, TetCAR), and tumor microenvironment shielding (dSHP2).
- The company reported net product revenue of $41.2 million for Q3 2026, up from $21.1 million in the same period prior year, driven by increased demand and UK market launch.
- Autolus reported a net loss of $55.1 million for Q3 2026 and an accumulated deficit of $1,552.6 million as of September 30, 2026.
- As of September 30, 2026, Autolus had cash and cash equivalents of $245.4 million and current assets of $366.8 million, with current liabilities of $98.6 million, resulting in a current ratio of 3.72 and cash ratio of 2.49.
- The company entered a senior secured notes facility with Perceptive in July 2026, initially issuing $75 million with an additional $25 million borrowing capacity and potential for $150 million more upon revenue milestones.
- Autolus uses Cardinal Health as an agent to deliver AUCATZYL to authorized treatment centers (ATCs), recognizing revenue when the patient receives the final dose.
- Research and development expenses include clinical trial costs, manufacturing scale-up, employee expenses, and license fees, with expected increases as clinical trials progress.
- The company faces risks including compliance with financial covenants under its notes facility, increased expenses due to transitioning to U.S. domestic issuer status, and uncertainties in clinical development and commercialization.
Generated 2026-11-11
- S1 | 2026-03-27 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-10 | www.nasdaq.com | Autolus (AUTL) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/autolus-autl-q3-2026-earnings-call-transcript
- N2 | 2026-08-18 | www.nasdaq.com | Autolus (AUTL) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/autolus-autl-q2-2026-earnings-call-transcript
- N3 | 2026-08-12 | www.nasdaq.com | Autolus Q2 Net Loss Narrows As AUCATZYL Sales Surge 119%; CARLYSLE Data Expected By Year-End | https://www.nasdaq.com/articles/autolus-q2-net-loss-narrows-aucatzyl-sales-surge-119-carlysle-data-expected-year-end
- N4 | 2026-08-11 | www.nasdaq.com | Autolus Therapeutics Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/autolus-therapeutics-q2-earnings-call-highlights
- N5 | 2026-08-11 | www.nasdaq.com | Autolus Therapeutics' AUCATZYL Q2 Revenue Surges 119%; Boosts FY26 Outlook | https://www.nasdaq.com/articles/autolus-therapeutics-aucatzyl-q2-revenue-surges-119-boosts-fy26-outlook
- N6 | 2026-08-04 | www.nasdaq.com | Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum | https://www.nasdaq.com/articles/top-biotech-gainers-upc-cuts-loss-cpix-gains-ahead-q2-results-autl-builds-commercial
- N7 | 2026-07-08 | www.nasdaq.com | 3 Cancer Stocks to Watch as Oncology Innovation Accelerates | https://www.nasdaq.com/articles/3-cancer-stocks-watch-oncology-innovation-accelerates
- N8 | 2026-06-23 | www.nasdaq.com | Tango Appoints Robert Azelby To Board Of Directors | https://www.nasdaq.com/articles/tango-appoints-robert-azelby-board-directors
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


